Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials
2024

Infantile Krabbe Disease and Endpoints for Trials

Sample size: 137 publication 10 minutes Evidence: high

Author Information

Author(s): Greco Melissa R., Lopez Mabel A., Beltran‐Quintero Maria L., Tuc Bengur Ecenur, Poe Michele D., Escolar Maria L.

Primary Institution: University of Pittsburgh

Hypothesis

The study aims to document disease progression in infantile-onset Krabbe disease and evaluate the outcomes of hematopoietic stem cell transplantation.

Conclusion

Infantile Krabbe disease with onset before 12 months is rapidly progressive, and timely HSCT is crucial to prevent irreversible brain damage.

Supporting Evidence

  • Patients with symptomatic HSCT had a median survival of 5 years, while asymptomatic patients had a median survival of 15.5 years.
  • Initial symptoms included irritability, developmental delay, and feeding difficulties.
  • HSCT did not prevent the progression of peripheral nerve disease.

Takeaway

This study looks at babies with a rare disease called Krabbe disease and how a special treatment can help them live longer and feel better.

Methodology

Patients with infantile Krabbe disease were prospectively evaluated using standardized protocols and analyzed with descriptive statistics and Kaplan–Meier survival curves.

Potential Biases

Implicit bias may exist regarding the patients followed longitudinally, as those with less severe symptoms were more likely to be included.

Limitations

Challenges included obtaining outside medical records and ensuring longitudinal follow-up due to patient symptoms and other factors.

Participant Demographics

The study included 137 children (68 males and 69 females) with infantile Krabbe disease.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1002/acn3.52114

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication